A real-life study of the effectiveness of different pharmacological approaches to the treatment of smoking cessation: Re-discussing the predictors of success

Clinics

Volumn 66, Issue 1, 2011, Pages 65-71

  Prado, Gustavo Faibischew ^a   Lombardi, Elisa Maria Siqueira ^a   Bussacos, Marco Antônio ^a   Arrabal Fernandes, Frederico Leon ^a   Terra Filho, Mário ^a   Santos, Ubiratan de Paula ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cognitive behavioral; Combined therapy; General practice; Nortriptyline; Weight gain

Indexed keywords

EID: 79952961459     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000100012     Document Type: Article

References (22)

1. Frieden TR, Bloomberg MR. How to prevent 100 million deaths from tobacco. Lancet. 2007;369:1758-61, doi: 10.1016/S0140-6736(07)60782-X.
2. Aveyard P, West R. Managing smoking cessation. BMJ. 2007;335:37-41, doi: 10.1136/bmj.39252.591806.47.
3. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med. 2000;18:305-11, doi: 10.1016/S0749-3797(00)00124-0.
4. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1): CD000146.
5. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. Controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-91, doi: 10.1056/NEJM199903043400903.
6. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med. 2001;135:423-33.
7. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective {alpha}4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placeboand bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166:1561-8, doi: 10.1001/archinte.166.15.1561.
8. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006;296:47-55, doi: 10.1001/jama.296.1.47.
9. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998;158:2035-9, doi: 10.1001/archinte.158.18.2035.
10. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159:2033-8, doi: 10.1001/archinte.159.17.2033.
11. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM IV), 4th ed, Washington, DC: American Psychiatric Association. 1994.
12. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
13. Perkins KA, Scott MA. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10:1245-51, doi: 10. 1080/14622200802097506.
14. Munafò M, Bradburn M, Bowes L, David S. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res. 2004;6:769-76, doi: 10.1080/14622200410001696556.
15. Menezes AM, Lopez MV, Hallal PC, Muiño A, Perez-Padilla R, Jardim JR, et al. Prevalence of smoking and incidence of initiation in the Latin American adult population: the PLATINO study. BMC Public Health. 2009;9:151-8, doi: 10.1186/1471-2458-9-151.
16. Klesges RC, Winders SE, Meyers AW, Eck LH, Ward KD, Hultquist CM, et al. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol. 1997;65:286-291, doi: 10. 1037/0022-006X.65.2.286.
17. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med. 1991;324:739-45, doi: 10.1056/NEJM199103143241106.
18. Haggsträm FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm Pharmacol Ther. 2006;19:205-9, doi: 10.1016/j.pupt.2005.05.003.
19. Prochazka AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med. 2004;164:2229-33, doi: 10.1001/archinte.164.20.2229.
20. Costa CL, Younes RN, Lourenço MTC. Stopping smoking: a prospective randomized, double-blind study comparing nortriptyline to placebo. Chest. 2002;122:403-8, doi: 10.1378/chest.122.2.403.
21. Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ. 2008;336:1223-7, doi: 10.1136/bmj.39545.852616.BE.
22. Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction. 2005;100:317-26, doi: 10.1111/j.1360-0443.2005. 00998.x.